InspireMD (NYSEAMERICAN:NSPR) Trading 12.7% Higher

InspireMD Inc (NYSEAMERICAN:NSPR) traded up 12.7% during trading on Tuesday . The company traded as high as $3.58 and last traded at $3.28, 295,885 shares changed hands during trading. An increase of 109% from the average session volume of 141,776 shares. The stock had previously closed at $2.91.

Separately, HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of InspireMD in a research note on Monday, August 19th.

InspireMD (NYSEAMERICAN:NSPR) last issued its earnings results on Tuesday, August 6th. The medical equipment provider reported ($1.59) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.00) by $0.41. The business had revenue of $1.35 million for the quarter, compared to the consensus estimate of $1.30 million.

An institutional investor recently bought a new position in InspireMD stock. Bank of New York Mellon Corp acquired a new position in InspireMD Inc (NYSEAMERICAN:NSPR) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 23,946 shares of the medical equipment provider’s stock, valued at approximately $82,000. Bank of New York Mellon Corp owned 1.76% of InspireMD as of its most recent filing with the SEC.

InspireMD Company Profile (NYSEAMERICAN:NSPR)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions.

See Also: FAANG Stocks

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.